{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-010422","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.521573+00:00","generated_at":"2026-05-25T09:52:04.898133+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive starts Anaphylm NDA filing; Q4 net loss $17.1M; 2025 revenue guidance $47-56M","bullets":["Q4 2024 total revenues $11.9M, down 10% YoY; full-year revenues $57.6M, up 14%.","Q4 net loss $17.1M ($0.19/sh) vs $8.1M loss ($0.12/sh) YoY; FY net loss $44.1M ($0.51/sh) vs $7.9M ($0.13/sh).","Anaphylm NDA submission started, FDA acceptance expected Q2 2025; launch targeted Q1 2026 if approved.","AQST-108 Phase 2a in alopecia areata to begin Q2 2025; Libervant court ruling appealed, product remains on market.","Pro-forma cash ~$93M including $21.4M ATM proceeds in Feb 2025; 2025 revenue guidance $47-56M, Non-GAAP EBITDA loss $46-53M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-010422","json":"https://secwatch.observer/filing/0001628280-25-010422.json","markdown":"https://secwatch.observer/filing/0001628280-25-010422.md","text":"https://secwatch.observer/filing/0001628280-25-010422.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/0001628280-25-010422-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025010422/aqst-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T09:52:04.898133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}